|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,898.50 GBX | -0.18% |
|
+0.66% | +4.06% |
| 05-20 | GSK Begins Negotiations for Multiple Myeloma Treatment in Canada | MT |
| 05-20 | GSK, Pan-Canadian Pharmaceutical Alliance Start Talks for Blenrep to Treat Blood Cancer | MT |
| Capitalization | 75.79B 102B 87.62B 80.21B 140B 9,842B 142B 951B 372B 4,646B 382B 374B 16,183B | P/E ratio 2026 * |
12.1x | P/E ratio 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise value | 88.07B 118B 102B 93.22B 163B 11,437B 165B 1,105B 432B 5,399B 444B 435B 18,806B | EV / Sales 2026 * |
2.61x | EV / Sales 2027 * | 2.41x |
| Free-Float |
92.3% | Yield 2026 * |
3.68% | Yield 2027 * | 3.86% |
Last Transcript: GSK plc
| 1 day | -0.18% | ||
| 1 week | +0.66% | ||
| Current month | -1.56% | ||
| 1 month | -11.45% | ||
| 3 months | -14.21% | ||
| 6 months | +7.84% | ||
| Current year | +4.06% |
| 1 week | 1,690 |  | 1,914.5 |
| 1 month | 1,690 | | 2,095 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.61% | 3.15% | 27 M€ | |
| +12.08% | 2.51% | 12 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.18% | +0.66% | +34.12% | +33.34% | 102B | |
| -0.25% | +0.31% | +36.39% | +130.32% | 911B | |
| -0.30% | -0.48% | +49.24% | +44.31% | 554B | |
| -0.68% | +1.82% | +14.85% | +46.30% | 378B | |
| -0.42% | +2.53% | +24.56% | +13.82% | 333B | |
| +0.50% | +1.34% | +33.90% | +16.15% | 288B | |
| -0.42% | +1.49% | +27.07% | +30.97% | 287B | |
| -1.09% | -0.40% | +44.93% | -2.16% | 282B | |
| +0.31% | -3.61% | -36.78% | -49.84% | 198B | |
| +0.25% | -1.45% | +20.57% | +48.41% | 179B | |
| Average | -0.27% | +0.91% | +24.89% | +31.16% | 351.11B | |
| Weighted average by Cap. | -0.39% | +1.16% | +29.71% | +51.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.76B 45.4B 39.04B 35.73B 62.39B 4,385B 63.39B 424B 166B 2,070B 170B 167B 7,209B | 35.4B 47.6B 40.93B 37.47B 65.41B 4,597B 66.46B 444B 174B 2,170B 179B 175B 7,559B |
| Net income | 6.3B 8.47B 7.29B 6.67B 11.65B 819B 11.83B 79.08B 30.95B 386B 31.8B 31.13B 1,346B | 6.73B 9.05B 7.78B 7.12B 12.44B 874B 12.64B 84.46B 33.05B 413B 33.96B 33.24B 1,437B |
| Net Debt | 12.29B 16.52B 14.2B 13B 22.7B 1,595B 23.07B 154B 60.32B 753B 61.99B 60.68B 2,623B | 9.41B 12.65B 10.87B 9.95B 17.38B 1,221B 17.66B 118B 46.18B 577B 47.45B 46.45B 2,008B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-05-20 | 1,898.50 p | -0.18% | 4,658,190 |
| 26-05-19 | 1,902.00 p | +1.36% | 4,651,353 |
| 26-05-18 | 1,876.50 p | +0.75% | 3,355,420 |
| 26-05-15 | 1,862.50 p | -0.53% | 11,582,700 |
| 26-05-14 | 1,872.50 p | -0.72% | 4,264,268 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition